Clinical Trial: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07217119) titled 'Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM' on Oct. 13.

Brief Summary: The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Study Start Date: Nov. 26, 2019

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma

Intervention: DRUG: Belantamab mafodotin

Belan...